Dementia News and Research

Latest Dementia News and Research

'Village' movement and community health clinics offer alternative models of care

"The village movement dates to the 2001 founding of Beacon Hill Village in Boston. This year, the Village to Village Network launched to help other communities create their own senior support groups. Other sites created to help arrange help for seniors who want to live independently at home: Senior Helpers' services include companionship, conversation, meal planning and house cleaning as well as Alzheimer's and dementia care."

23 Aug 2010

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

23 Aug 2010

GM-CSF protein reduces AD pathology, reverses memory loss: Study

A signaling protein released during rheumatoid arthritis dramatically reduced Alzheimer's disease pathology and reversed the memory impairment of mice bred to develop symptoms of the neurodegenerative disease, a new study by the University of South Florida reports. Researchers found that the protein, GM-CSF, likely stimulates the body's natural scavenger cells to attack and remove Alzheimer's amyloid deposits in the brain.

23 Aug 2010

Study finds burnout progressively develops among medical students

More than 40 percent of third-year medical students have symptoms of moderate to severe burnout, according to a study in the August Southern Medical Journal, official journal of the Southern Medical Association.

19 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

This summer, more than 55 researchers participating in the Alzheimer's Breakthrough Ride are cycling relay-style across the country, collecting petition signatures asking Congress to make Alzheimer's disease a national priority. The public response to the petition has been so overwhelming that as the Alzheimer's Breakthrough Riders hit the halfway point in their 67-day route from San Francisco to Washington, D.C. on August 18, they are already more than 80% of the way to their goal of 50,000 signatures.

18 Aug 2010

Brain trauma in sports associated with motor neuron disease, researchers find

The Center for the Study of Traumatic Encephalopathy at Boston University School of Medicine and Department of Veterans Affairs announced today that they have provided the first pathological evidence that repetitive head trauma experienced in collision sports is associated with motor neuron disease, a neurological condition that affects voluntary muscle movements.

18 Aug 2010

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Professional athletes with repetitive head trauma and possibly others with a history of head injuries many years previously may be prone the development of a motor neuron disease similar to amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), reports a study in the September Journal of Neuropathology & Experimental Neurology, official journal of the American Association of Neuropathologists, Inc.

18 Aug 2010

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

18 Aug 2010

Moderate wine consumption associated with better cognitive performance

A large prospective study of 5033 men and women in the Troms- Study in northern Norway has reported that moderate wine consumption is independently associated with better performance on cognitive tests. The subjects (average age 58 and free of stroke) were followed over 7 years during which they were tested with a range of cognitive function tests.

18 Aug 2010

Holotranscobalamin protein may be key to early detection of cognitive decline

B vitamins-B-6, B-12 and folate-all nourish the brain. But much remains to be discovered about the relation between these essential nutrients and our brainpower.

18 Aug 2010

Psychological stress in middle age increases risk of dementia later in life

Psychological stress in middle age could lead to the development of dementia later in life, especially Alzheimer's disease, reveals research from the University of Gothenburg, Sweden. Based on data from a study which followed women for 35 years, this is the first research in Sweden to indicate a link between stress and dementia.

17 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

Psychological stress in middle age can lead to dementia: Research

16 Aug 2010

Adverse effects in childhood lead to immune impairment later in life

The emotional pains we suffer in childhood can lead to weakened immune systems later in life, according to a new study.Based on this new research, the amount of this immune impairment even enhances that caused by the stress of caregiving later in life."What happens in childhood really matters when it comes to your immune response in the latter part of your life," explained Janice Kiecolt-Glaser, professor of psychology and psychiatry at Ohio State University. She explained her work at the annual meeting of the American Psychological Association in San Diego.

16 Aug 2010

Researchers identify second type of complete sporadic disease

A new sporadic prion protein disease has been discovered. Variably protease-sensitive prionopathy, as it has been named, is the second type of complete sporadic disease to be identified since Creutzfeldt-Jakob disease was reported in the 1920s. The landmark finding from the National Prion Disease Pathology Surveillance Center at Case Western Reserve University is published in the August issue of Annals of Neurology.

13 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Mental health bill for 2008 was $5.3 billion: Report

According to the Australian Institute of Health and Welfare (AIHW), the country is spending more and more to deal with its mental ailment burden. This emerged from a report from the AIHW saying that finances spent on mental health services between 2007 to 2008 were $5.3 billion. Of this around 60 per cent came from state and territory governments, 36 per cent from the Commonwealth, and the rest from private health funds.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Researchers identify perforant path brain passage associated with Alzheimer's disease

With the help of volunteers aged 18 to 89, UC Irvine researchers have identified for the first time in humans a long-hidden part of the brain called the perforant path. Scientists have struggled for decades to locate the tiny passage, which is believed to deteriorate gradually as part of normal aging and far more quickly due to Alzheimer's disease.

11 Aug 2010

Dementia News and Research

Latest Dementia News and Research

'Village' movement and community health clinics offer alternative models of care

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

GM-CSF protein reduces AD pathology, reverses memory loss: Study

Study finds burnout progressively develops among medical students

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

Brain trauma in sports associated with motor neuron disease, researchers find

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Moderate wine consumption associated with better cognitive performance

Holotranscobalamin protein may be key to early detection of cognitive decline

Psychological stress in middle age increases risk of dementia later in life

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Psychological stress in middle age can lead to dementia: Research

Adverse effects in childhood lead to immune impairment later in life

Researchers identify second type of complete sporadic disease

Intellect Neurosciences receives patent for insulin sensitizer drugs

Mental health bill for 2008 was $5.3 billion: Report

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Researchers identify perforant path brain passage associated with Alzheimer's disease

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Dementia News and Research

Latest Dementia News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in